AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32750626 — intervention group
Group type: EXPERIMENTAL
Intervention: Most intensive intervention group
Number of subjects: 595
Study 32750626 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 595
Study 33340263 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (2-12 mg/day)
Number of subjects: 277
Study 33340263 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (8 mg/day)
Number of subjects: 277
Study 33340263 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 277
Study 32314053 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-week triathlon exercise training program
Number of subjects: 46
Study 32314053 — intervention group
Group type: COMPARATOR
Intervention: Untrained control group (n=16)
Number of subjects: 46
Study 35133286 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral intervention with asynchronous therapist support
Number of subjects: 87
Study 35133286 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 87
Study 32234295 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with Azacytidine (AZA) at 32 mg/m2 for 5 days every 28 days
Number of subjects: 32
Study 32234295 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive treatment with Azacytidine (AZA) at 75 mg/m2 for 5 or 7 days per cycle
Number of subjects: 32
Study 32234295 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor lymphocyte infusions (DLIs)
Number of subjects: 32
Study 32234295 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft-versus-host disease (GvHD) management
Number of subjects: 32
Study 32234295 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment suspension
Number of subjects: 32
Study 35945827 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for diagnosing CRC using hemoglobin-to-platelet ratio, fibrinogen-albumin ratio (FAR), albumin-globulin ratio (A/G), platelet-lymphocyte ratio, carcinoembryonic antigen (CEA), and thrombin time (TT).
Number of subjects: 856
Study 35945827 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for diagnosing CRC stage using prothrombin time (PT), TT, CEA, A/G, FAR, and hemoglobin-to-platelet ratio (HPR).
Number of subjects: 856
Study 35945827 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for diagnosing CRC grade using PT, TT, A/G, plateletcrit, FAR, and HPR.
Number of subjects: 856
Study 33637074 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral ibuprofen
Number of subjects: 7000
Study 33637074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7000
Study 32632546 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CTA
Number of subjects: 180
Study 32632546 — intervention group
Group type: COMPARATOR
Intervention: Functional testing
Number of subjects: 180
Study 33608400 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled sedation strategy
Number of subjects: 250
Study 33608400 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sedation strategy
Number of subjects: 250
Study 32149826 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible duty-hour policy
Number of subjects: 3750
Study 34294144 — intervention group
Group type: EXPERIMENTAL
Intervention: Baidu Jieduan granules (twice a day for 14 days)
Number of subjects: 300
Study 34294144 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 300
Study 33901041 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation combined with neuromuscular electrical stimulation
Number of subjects: 26
Study 33901041 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional rehabilitation only)
Number of subjects: 26
Study 32464822 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 3 (HM3)
Number of subjects: 1020
Study 32464822 — intervention group
Group type: COMPARATOR
Intervention: HeartMate II (HMII)
Number of subjects: 1020
Study 34518313 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg orally twice daily and capivasertib orally twice daily on a 4-day on 3-day off schedule (DL1: 400 mg, DL-1: 320 mg)
Number of subjects: 38
Study 34518313 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg orally twice daily and capivasertib orally twice daily on a 4-day on 3-day off schedule
Number of subjects: 38
Study 34518313 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib and capivasertib
Number of subjects: 38
Study 32589237 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-orifice catheter (MOC)
Number of subjects: 58
Study 32589237 — intervention group
Group type: COMPARATOR
Intervention: End-hole catheter (EHC)
Number of subjects: 58
Study 34736073 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month multicomponent intervention
Number of subjects: 112
Study 34736073 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 112
Study 32819292 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal blood purification (hemoadsorption) via resin-directed hemoperfusion using continuous renal replacement therapy (CVVH) for three sessions
Number of subjects: 10
Study 32819292 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal blood purification (hemoadsorption)
Number of subjects: 10
Study 34343394 — intervention group
Group type: COMPARATOR
Intervention: Active stimulation for brachial plexus leads
Number of subjects: 61
Study 34343394 — intervention group
Group type: COMPARATOR
Intervention: Active stimulation for sciatic nerve leads
Number of subjects: 61
Study 33135552 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured family meeting
Number of subjects: 297
Study 33135552 — intervention group
Group type: COMPARATOR
Intervention: Control group (no family meeting)
Number of subjects: 297
Study 32381160 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg or placebo administered subcutaneously every 2 weeks, titrated to 150 mg if LDL-C remained ≥50 mg/dl.
Number of subjects: 18924
Study 35905318 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session group counseling course
Number of subjects: 1680
Study 35905318 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed (control group)
Number of subjects: 1680
Study 33881579 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (TIVA)
Number of subjects: 132
Study 33881579 — intervention group
Group type: COMPARATOR
Intervention: Inhalation Anesthesia (INHA) with desflurane (DES)
Number of subjects: 132
Study 34842984 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 362
Study 34842984 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 362
Study 34842984 — intervention group
Group type: EXPERIMENTAL
Intervention: CST fluctuation quartiles (4th vs 1st)
Number of subjects: 362
Study 33417284 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cetirizine 1% applied daily (1 mL) for 6 months
Number of subjects: 60
Study 33417284 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution applied daily (1 mL) for 6 months
Number of subjects: 60
Study 32348537 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment
Number of subjects: 235
Study 36210397 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieve catheter-guided cryoballoon ablation with additional EnSite voltage maps
Number of subjects: 100
Study 36210397 — intervention group
Group type: COMPARATOR
Intervention: Achieve catheter-guided cryoballoon ablation (control group)
Number of subjects: 100
Study 36210397 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieve Plus group
Number of subjects: 100
Study 36210397 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 32860716 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesame oil (SO)
Number of subjects: 92
Study 32860716 — intervention group
Group type: COMPARATOR
Intervention: Canola oil (CO)
Number of subjects: 92
Study 32860716 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesame-canola oil (SCO)
Number of subjects: 92
Study 35843915 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1 mg/kg and continuous infusion at 2 mg/kg/h)
Number of subjects: 120
Study 35843915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 120
Study 35843915 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (continuous infusion at 1.5 gr/kg)
Number of subjects: 120
Study 33440207 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological thromboprophylaxis (89% of patients)
Number of subjects: 73
Study 33440207 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate, room-air oxygen saturation (spO2), D-dimer, and C-reactive protein (CRP) levels at admission
Number of subjects: 73
Study 33440207 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score constructed from heart rate, spO2, D-dimer, and CRP levels
Number of subjects: 73
Study 36113378 — intervention group
Group type: EXPERIMENTAL
Intervention: JR-142 at 0.25 mg/kg
Number of subjects: 31
Study 36113378 — intervention group
Group type: EXPERIMENTAL
Intervention: JR-142 at 0.5 mg/kg
Number of subjects: 31
Study 36113378 — intervention group
Group type: EXPERIMENTAL
Intervention: JR-142 at 1.0 mg/kg
Number of subjects: 31
Study 36113378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 36113378 — intervention group
Group type: EXPERIMENTAL
Intervention: JR-142 (all dosages)
Number of subjects: 31
Study 33713840 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care adapted for co-occurring disorders (CC-COD)
Number of subjects: 900
Study 33713840 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 900
Study 33621809 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (5 mcg, subcutaneously)
Number of subjects: 13
Study 33621809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 32819740 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-minute session with a certified therapy dog and handler
Number of subjects: 221
Study 32819740 — intervention group
Group type: COMPARATOR
Intervention: 20-minute session with a handler only (control group)
Number of subjects: 221
Study 35756401 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated psychobehavioral care
Number of subjects: 100
Study 35756401 — intervention group
Group type: COMPARATOR
Intervention: Conventional psychobehavioral care
Number of subjects: 100
Study 33405475 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based motivational interviewing followed by a 6-month community-based intervention and multiagency support
Number of subjects: 0
Study 32591475 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab 300 mg
Number of subjects: 0
Study 32591475 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab 600 mg
Number of subjects: 0
Study 32591475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34634454 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTIVA Bone Health Program for six months
Number of subjects: 100
Study 34634454 — intervention group
Group type: COMPARATOR
Intervention: inactive
Number of subjects: 100
Study 33586543 — intervention group
Group type: EXPERIMENTAL
Intervention: VIPP‐PRE
Number of subjects: 73
Study 33586543 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 73
Study 32624460 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI TIMI 3 flow
Number of subjects: 96
Study 32624460 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI TMPG grade 3
Number of subjects: 96
Study 32624460 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI TMPG
Number of subjects: 96
Study 34953443 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone (AA+P)
Number of subjects: 1199
Study 34953443 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone (AA+P) in lung metastases patients
Number of subjects: 1199
Study 34953443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1199
Study 35669371 — intervention group
Group type: EXPERIMENTAL
Intervention: AR‐based rehabilitation methods
Number of subjects: 40
Study 35669371 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation methods
Number of subjects: 40
Study 34138478 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (200 mg/d) for 7 days or until hospital discharge
Number of subjects: 30
Study 34138478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32967151 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetraselmis chuii microalgae supplementation (200 mg per day)
Number of subjects: 32
Study 32967151 — intervention group
Group type: COMPARATOR
Intervention: Control group (lactose powder 200 mg per day)
Number of subjects: 32
Study 35324908 — intervention group
Group type: EXPERIMENTAL
Intervention: BASIL+ intervention (Behavioural Activation), delivered remotely, up to eight sessions with a self-help booklet.
Number of subjects: 0
Study 35324908 — intervention group
Group type: EXPERIMENTAL
Intervention: BASIL+ intervention (Behavioural Activation)
Number of subjects: 0
Study 35324908 — intervention group
Group type: COMPARATOR
Intervention: Usual care with additional signposting to self-help resources.
Number of subjects: 0
Study 32946459 — intervention group
Group type: EXPERIMENTAL
Intervention: 32-item Motor Function Measure (MFM32)
Number of subjects: 110
Study 32618048 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 58
Study 32618048 — intervention group
Group type: COMPARATOR
Intervention: Levocetirizine 5 mg
Number of subjects: 58
Study 36279463 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed treatment in randomized experiments
Number of subjects: 0
Study 36279463 — intervention group
Group type: EXPERIMENTAL
Intervention: Historical baseline measurements prior to the experiment
Number of subjects: 0
Study 36368915 — intervention group
Group type: COMPARATOR
Intervention: Group P (0 mg.kg-1 S-ketamine)
Number of subjects: 120
Study 36368915 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S0.3 (0.3 mg.kg-1 S-ketamine)
Number of subjects: 120
Study 36368915 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S0.5 (0.5 mg.kg-1 S-ketamine)
Number of subjects: 120
Study 36368915 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S0.7 (0.7 mg.kg-1 S-ketamine)
Number of subjects: 120
Study 36368915 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S0.3
Number of subjects: 120
Study 36368915 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S0.5
Number of subjects: 120
Study 36368915 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S0.7
Number of subjects: 120
Study 36368915 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S0.5 and Group S0.7
Number of subjects: 120
Study 36368915 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study 32255706 — intervention group
Group type: EXPERIMENTAL
Intervention: Flicker light stimulation in NTG patients
Number of subjects: 12
Study 32255706 — intervention group
Group type: COMPARATOR
Intervention: Flicker light stimulation in healthy individuals
Number of subjects: 12
Study 34975349 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb rehabilitation protocol (LLRP)
Number of subjects: 50
Study 34975349 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - Instruction of daily care (IDC) only
Number of subjects: 50
Study 32064970 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/day omega-3 fatty acids from a plant-based fatty acid supplement
Number of subjects: 0
Study 32064970 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ingestion of omega-3 fatty acids and encapsulated fruit, vegetable and berry (FVB) juice powder concentrate
Number of subjects: 0
Study 616536630 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-specific school-based program
Number of subjects: 652
Study 616536630 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 652
Study 34347895 — intervention group
Group type: EXPERIMENTAL
Intervention: articaine (4% / 2 mL)
Number of subjects: 120
Study 34347895 — intervention group
Group type: EXPERIMENTAL
Intervention: tramadol (100 mg/2 mL)
Number of subjects: 120
Study 34347895 — intervention group
Group type: EXPERIMENTAL
Intervention: dexamethasone (8 mg/2 mL)
Number of subjects: 120
Study 34347895 — intervention group
Group type: COMPARATOR
Intervention: control group (normal saline)
Number of subjects: 120
Study 33904045 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives on GP level
Number of subjects: 3838
Study 33904045 — intervention group
Group type: COMPARATOR
Intervention: Control group (no financial incentives)
Number of subjects: 3838
Study 34743963 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% nanoHAP dental lotion
Number of subjects: 30
Study 34743963 — intervention group
Group type: COMPARATOR
Intervention: Placebo dental lotion
Number of subjects: 30
Study 36117136 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral scan with markers
Number of subjects: 8
Study 36117136 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral scan without markers
Number of subjects: 8
Study 36117136 — intervention group
Group type: COMPARATOR
Intervention: Conventional impression technique
Number of subjects: 8
Study 33323529 — intervention group
Group type: EXPERIMENTAL
Intervention: Poseltinib 5 mg
Number of subjects: 286
Study 33323529 — intervention group
Group type: EXPERIMENTAL
Intervention: Poseltinib 10 mg
Number of subjects: 286
Study 33323529 — intervention group
Group type: EXPERIMENTAL
Intervention: Poseltinib 30 mg
Number of subjects: 286
Study 33323529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 35719221 — intervention group
Group type: EXPERIMENTAL
Intervention: LSMT (unilateral lumbar PA mobilization at L‐4)
Number of subjects: 30
Study 35719221 — intervention group
Group type: EXPERIMENTAL
Intervention: SS (static stretching)
Number of subjects: 30
Study 35719221 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of LSMT and SS
Number of subjects: 30
Study 35719221 — intervention group
Group type: COMPARATOR
Intervention: Control (LSMT and SS)
Number of subjects: 30
Study 33855653 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg TID plus choline alphoscerate 600 mg BID
Number of subjects: 62
Study 33855653 — intervention group
Group type: COMPARATOR
Intervention: Nimodipine 30 mg TID plus placebo BID
Number of subjects: 62
Study 35951060 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol inhalation combined with a vibration expectoration machine
Number of subjects: 110
Study 33829344 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutetium-Octreotate (LO) treatment
Number of subjects: 0
Study 33829344 — intervention group
Group type: COMPARATOR
Intervention: Octreotide long-acting release (O-LAR)
Number of subjects: 0
Study 35036626 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalized brief cognitive task intervention (remotely delivered, guided)
Number of subjects: 0
Study 35036626 — intervention group
Group type: COMPARATOR
Intervention: Active (attention placebo) control
Number of subjects: 0
Study 34506918 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga module for anger management
Number of subjects: 50
Study 36199075 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Flinders Program plus usual care
Number of subjects: 0
Study 36199075 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 33722420 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (PARP inhibitor)
Number of subjects: 0
Study 33722420 — intervention group
Group type: COMPARATOR
Intervention: Control arm (not specified)
Number of subjects: 0
Study 33722420 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic progression-free survival
Number of subjects: 0
Study 33722420 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutations in homologous recombination repair genes other than BRCA1, BRCA2, and ATM
Number of subjects: 0
Study 33372114 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 module classroom‐based intervention program
Number of subjects: 434
Study 33372114 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 434
Study 36310622 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training for 12 weeks followed by 12 weeks of self-practice
Number of subjects: 0
Study 36310622 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group maintaining usual lifestyle for 24 weeks
Number of subjects: 0
Study 36310622 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training for 12 weeks
Number of subjects: 0
Study 32265117 — intervention group
Group type: EXPERIMENTAL
Intervention: High completion group (4-5 cycles of irinotecan)
Number of subjects: 371
Study 32265117 — intervention group
Group type: COMPARATOR
Intervention: Low completion group (1-3 cycles of irinotecan)
Number of subjects: 371
Study 32265117 — intervention group
Group type: EXPERIMENTAL
Intervention: CinClare group (high completion)
Number of subjects: 371
Study 32265117 — intervention group
Group type: COMPARATOR
Intervention: CinClare group (low completion)
Number of subjects: 371
Study 32265117 — intervention group
Group type: EXPERIMENTAL
Intervention: High completion rates across risk groups
Number of subjects: 371
Study 33753430 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention about work-related stress, including training for GPs, screening of patients' work-related stress, feedback to patients on screening results and discussion of measures at GP consultation
Number of subjects: 271
Study 33753430 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 271
Study 33753430 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 271
Study 35721170 — intervention group
Group type: EXPERIMENTAL
Intervention: XueBiJing treatment (100 ml, q12 h for 5–7 days)
Number of subjects: 425
Study 35721170 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 425
Study 35721170 — intervention group
Group type: EXPERIMENTAL
Intervention: XueBiJing treatment and Placebo treatment
Number of subjects: 425
Study 32534972 — intervention group
Group type: EXPERIMENTAL
Intervention: VectorFlow catheter
Number of subjects: 100
Study 32534972 — intervention group
Group type: COMPARATOR
Intervention: Palindrome catheter
Number of subjects: 100